We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
-15.35%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.5M
AUM Growth
-$40.1M
Cap. Flow
+$254M
Cap. Flow %
266.32%
Top 10 Hldgs %
44.8%
Holding
389
New
183
Increased
50
Reduced
47
Closed
99

Top Buys

1
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.6M
2
BAX icon
Baxter International
BAX
+$3.81M
3
AKBA icon
Akebia Therapeutics
AKBA
+$2.87M
4
OTIC
Otonomy, Inc.
OTIC
+$2.46M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$1.81M

Top Sells

1
GILD icon
Gilead Sciences
GILD
+$8.82M
2
CELG
Celgene Corp
CELG
+$6.57M
3
DYAX
DYAX CORPORATION
DYAX
+$6.35M
4
CMG icon
Chipotle Mexican Grill
CMG
+$5.44M
5
VTRS icon
Viatris
VTRS
+$2.57M

Sector Composition

1 Healthcare 48.43%
2 Technology 4.06%
3 Consumer Discretionary 2.5%
4 Consumer Staples 1.74%
5 Materials 1.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIVO
226
CALL
DELISTED
TIVO INC
TIVO
$16K 0.02%
+24,000
New +$193K
AMAT icon
227
CALL
Applied Materials
AMAT
$421B
$15K 0.02%
+8,100
New +$148K
CTSH icon
228
CALL
Cognizant
CTSH
$21.2B
$15K 0.02%
+10,400
New +$605K
INSM icon
229
CALL
Insmed
INSM
$23.5B
$15K 0.02%
+21,600
New +$284K
FMI
230
CALL
DELISTED
Foundation Medicine, Inc.
FMI
$15K 0.02%
10,600
– –
TWC
231
PUT
DELISTED
TIME WARNER CABLE INC NEW COM STK
TWC
$15K 0.02%
+21,800
New +$4.12M
GLW icon
232
PUT
Corning
GLW
$133B
$14K 0.01%
+47,400
New +$879K
TTPH
233
CALL
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$14K 0.01%
+2,250
New +$225K
EW icon
234
PUT
Edwards Lifesciences
EW
$49.4B
$13K 0.01%
+21,000
New +$579K
KITE
235
PUT
DELISTED
Kite Pharma, Inc.
KITE
$13K 0.01%
+5,000
New +$242K
BA icon
236
PUT
Boeing
BA
$169B
$11K 0.01%
+5,000
New +$620K
GMED icon
237
PUT
Globus Medical
GMED
$10.5B
$11K 0.01%
+20,000
New +$489K
HLF icon
238
PUT
Herbalife
HLF
$1.24B
$11K 0.01%
+8,400
New +$217K
RGLS
239
PUT
DELISTED
Regulus Therapeutics
RGLS
$11K 0.01%
+42
New +$33.4K
AKBA icon
240
PUT
Akebia Therapeutics
AKBA
$359M
$10K 0.01%
+201,800
New +$1.64M
FIVE icon
241
PUT
Five Below
FIVE
$11.2B
$10K 0.01%
+49,600
New +$1.81M
GIS icon
242
PUT
General Mills
GIS
$20.3B
$10K 0.01%
+12,500
New +$727K
BIG
243
CALL
DELISTED
Big Lots, Inc.
BIG
$10K 0.01%
+21,200
New +$850K
SIOX
244
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$10K 0.01%
2,500
-538
-18% -$57.4K
ATHM icon
245
PUT
Autohome
ATHM
$2.48B
$9K 0.01%
+21,700
New +$571K
FOLD
246
PUT
DELISTED
Amicus Therapeutics
FOLD
$9K 0.01%
+25,000
New +$177K
ALXN
247
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$9K 0.01%
+10,000
New +$1.47M
TTPH
248
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$9K 0.01%
+94
New +$9.39K
ALDR
249
PUT
DELISTED
Alder Biopharmaceuticals
ALDR
$9K 0.01%
5,000
-10,600
-68% -$245K
HLF icon
250
CALL
Herbalife
HLF
$1.24B
$8K 0.01%
+13,400
New +$346K
8 9
10
11 12

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q1 2016 Portfolio in Review

As of Q1 2016, FT Options held 389 positions worth $95.5M, down 30% from $136M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

FT Options deployed $254M of net new capital in Q1 2016, opening 183 new positions and adding to 50 existing holdings. Its largest new stake was Baxter International: 100,000 shares worth $4.11M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Gilead Sciences, an estimated $8.82M trimmed.

  • FT Options's largest Q1 2016 buy was Baxter International: 100,000 shares worth $4.11M.
  • FT Options added most to Regeneron Pharmaceuticals in Q1 2016, an estimated $10.6M increase.
  • FT Options's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $8.82M.
  • FT Options fully exited Celgene Corp in Q1 2016, selling an estimated $6.57M.
  • FT Options's ten largest holdings make up 45% of its $95.5M portfolio in Q1 2016.
  • FT Options opened 183 new positions and closed 99 in Q1 2016.
  • FT Options's portfolio value fell 30% quarter-over-quarter to $95.5M.

Based on FT Options's 13F filing for Q1 2016, filed 9 May 2016.